CONTACT-02 Trial Results: Cabozantinib and Atezolizumab in Metastatic Prostate Cancer The combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) reduced the risk of disease progression or death by approximately 35% in …
Tag: